Risk assessment of neurotoxicity is mainly based on in vivo exposure, followed by tests on behaviour, physiology and pathology. In this study, an attempt to estimate lowest observed neurotoxic doses after single or repeated dose exposure was performed. Differentiated human neuroblastoma SH-SY5Y cells were exposed to acrylamide, lindane, parathion, paraoxon, phenytoin, diazepam or caffeine for 72 hours. The effects on protein synthesis and intracellular free Ca2+concentration were studied as physiological endpoints. Voltage operated Ca2 +channel function, acetylcholine receptor function and neurite degenerative effects were investigated as neurospecific endpoints for excitability, cholinergic signal transduction and axonopathy, respectively. The general cytotoxicity, determined as the total cellular protein levels after the 72 hours exposure period, was used for comparison to the specific endpoints and for estimation of acute lethality. The lowest concentration that induced 20% effect (EC 20) obtained for each compound, was used as a surrogate for the lowest neurotoxic level (LOEL) at the target site in vivo. The LOELs were integrated with data on adsorption, distribution, metabolism and excretion of the compounds in physiologically-based biokinetic (PBBK) models of the rat and the lowest observed effective doses (LOEDs) were estimated for the test compounds. A good correlation was observed between the estimated LOEDs and experimental LOEDs found in literature for rat for all test compounds, except for diazepam. However, when using in vitro data from the literature on diazepam's effect on gamma-amino butyric acid (GABA)A receptor function for the estimation of LOED, the correlation between the estimated and experimental LOEDs was improved from a 10 000-fold to a 10-fold difference. Our results indicate that it is possible to estimate LOEDs by integrating in vitro toxicity data as surrogates for lowest observed target tissue levels with PBBK models, provided that some knowledge about toxic mechanisms is known.Human & Experimental Toxicology (2007) 26, 333—338
Oecd.Guidance document for neurotoxicity testing. Series on testing and Assessment No 20: 2004; NNV/JM/MONO (2004)25.
2.
Påhlman S., Mamaeva S., Mayerson G., Mattson Mek, Bjelfman C., Örtoft E., Hammerling U.Human neuroblastoma cells in culture: A model for neuronal differentiation and function. Acta Physiologica Scandinavica1990; 140(Suppl. 592): 25—37.
3.
Nordin Andersson M, Walum E., Kjellstrand P., Forsby A.Acrylamide-induced effects on general and neurospecific cellular functions during exposure and recovery. Cell Biology andToxicology2003; 19: 43—51.
4.
Forsby A., Pilli F., Bianchi V., Walum E.Determinations of critical cellular neurotoxic concentrations in human neuroblastoma (SH-SY5Y) cell cultures. Alternatives to Laboratory Animals1995; 23: 800—11.
5.
Ekwall B., Barile FA, Castano A., Clemedson C. et al. MEIC evaluation of acute systemic toxicity. Part VI. The prediction of human toxicity by rodent LD50 values and results from 61 in vitro methods . Alternatives to Laboratory Animals1998; 26: 617—58.
6.
DeJongh J., Blaauboer BJSimulation of lindane kinetics in rats. Toxicology1997; 122: 1—9.
7.
DeJongh J., Nordin Andersson M, Ploeger BA, Forsby A.Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations. Toxicology and Applied Pharmacology1999a; 13: 261—68.
8.
DeJongh J., Forsby A., Houston BJ, Beckman M. et al. An integrated approach to the prediction of systemic toxicity using computer-based biokinetic models and biological in vitro test methods: overview of a prevalidation study based on the ECITTS project. Toxicology In Vitro1999b; 13: 549—54.
9.
Schulz H. and Feuer L.Anticonflict properties of the peptide Litoralon and of diazepam in rats. Acta Physiologica Hungarica1986; 67: 331—38.
10.
Halle W.The registry of cytotoxicity: Toxicity testing cultures to predict acute toxicity (LD50) and testing in animals. Alternatives to Laboratory Animals2003; 31: 89—198.
11.
NIH, National institute of health.Report on the international workshop on in vitro methods assessing acute systemic toxicity. 2001; Publication No. 01-4499, pp. 67—69.
12.
LoPachin RM and Lehning EJMechanism of calcium entry during axon injury and degeneration. Toxicology1997; 143: 233—44.
13.
Crofton K., Padilla S., Tilson HA, Anthony DC et al. The impact of dose rate on the neurotoxicity of acrylamide: The interaction of administrated dose, target tissue concentrations and functional effects. Toxicology and Applied Pharmacology1996; 139: 163—76.
14.
Swaynok J., Reid AR, and Doak GJCaffeine antinociception in the hot-plate and formalin tests and loco-motor stimulation: involvement of noradrenergic mechanisms. Pain1995; 61: 203—13.
15.
Desi I.Neurotoxicological effect of small quantities of lindane. Internationales Archiv furArbeitsmedizin1974; 33: 153—62.
16.
Tusell JM, Sunol C., Gelpi E., Rodriguez-Farré E.Effect of lindane at repeated low doses. Toxicology1988; 49: 375—79.
17.
Who.Lindane. Environmental health criteria1991; 124: 208 pp.
18.
Moser VCComparisons of the acute effects of cholineesterase inhibitors using a neurobehavioral screening battery in rats. Neurotoxicology andTeratology1995; 17: 617—25.
19.
Kulig BMSome behavioral effects of antiepileptic drugs during acute and prolonged treatment in the rat. Acta Neurologica Scandinavica Suppl.1981; 89: 59—67.
20.
Itier V., DePoorte H., Scatton B., Avent P.Protracted treatment with diazepam reduces benzodiazepine 1 receptor-mediated potentiation of gamma-amino butyric acid-induced currents in dissociated rat hippocampal neurons. Journal of Pharmacologic Experimental Therapeutics1996; 279: 1092—99.
